Latuda

Latuda is a brand name of lurasidone, approved by the FDA in the following formulation(s):

LATUDA (lurasidone hydrochloride - tablet; oral)

• 
  Manufacturer: SUNOVION
  
  Approval date: October 28, 2010
  
  Strength(s): 40MG, 80MG ^[RLD]

Has a generic version of Latuda been approved?

No. There is currently no therapeutically equivalent version of Latuda available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Latuda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Imide derivatives, and their production and use
  Patent 5,532,372
  Issued: July 2, 1996
  Inventor(s): Saji; Ikutaro & Muto; Masayuki & Tanno; Norihiko & Yoshigi; Mayumi
  Assignee(s): Sumitomo Pharmaceuticals Company, Ltd.
  An imide compound of the formula: ##STR1## wherein Z is a group of the formula: ##STR2## in which the substituents are defined herein, and n is an integer of 0 to 1; D is a group of the formula: EQU --(CH.sub.2).sub.p --A--(CH.sub.2).sub.q -- in which A is a non-aromatic hydrocarbon ring optionally bridged with a lower alkylene group or an oxygen atom, said non-aromatic hydrocarbon ring and said lower alkylene group being each optionally substituted with at least one lower alkyl, and p and q are each an integer of 0, 1 or 2; and Ar is an aromatic group, a heterocyclic aromatic group, a benzoyl group, a phenoxy group or a phenylthio group and G is >N--, >CH-- or >COH-- or Ar is a biphenylmethylidene group and G is >C.dbd., all of the above groups being each optionally substituted with at least one of lower alkyl, lower alkoxy and halogen; and its acid addition salts, useful as an antipsycotic agent.
  
  Patent expiration dates:
  
  
  • July 2, 2013
    
    ✓ 
    Drug substance
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 28, 2015 - NEW CHEMICAL ENTITY
  
  

See also...

• Latuda Consumer Information (Drugs.com)
• Latuda Consumer Information (Wolters Kluwer)
• Latuda Consumer Information (Cerner Multum)
• Latuda Advanced Consumer Information (Micromedex)
• Latuda AHFS DI Monographs (ASHP)
• Lurasidone Consumer Information (Wolters Kluwer)
• Lurasidone Consumer Information (Cerner Multum)
• Lurasidone Advanced Consumer Information (Micromedex)
• Lurasidone Hydrochloride AHFS DI Monographs (ASHP)